New strategies in lung cancer: Translating immunotherapy into clinical practice

Research output: Contribution to journalArticlepeer-review

30 Scopus citations


Recent breakthroughs in translating the early development of immunomodulatory antibodies into the clinic, notably with the anti-cytotoxic T-lymphocyte antigen-4 antibody, ipilimumab, have led to durable benefits and prolonged survival for a subgroup of patients with advanced melanoma. Subsequent studies have shown that related immune checkpoint antibodies, specifically those targeting the programmed death-1 pathway, have activity in non-small cell lung cancer. Non-small cell lung cancer is the commonest cause of cancer death worldwide and this exciting avenue of clinical investigation carries with it great promise and new challenges. In this article, we discuss recent developments in lung cancer immunotherapy, reviewing recent findings from therapeutic vaccine studies and in particular we focus on the refinement of immunomodulation as a therapeutic strategy in this challenging disease.

Original languageEnglish (US)
Pages (from-to)1067-1073
Number of pages7
JournalClinical Cancer Research
Issue number5
StatePublished - 2014

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'New strategies in lung cancer: Translating immunotherapy into clinical practice'. Together they form a unique fingerprint.

Cite this